In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

• Ngā kaituhi matua: Zhi Wang (Author), Ying Li (Author), Xueru He (Author), Yuhao Fu (Author), Yajing Li (Author), Xin Zhou (Author), Zhanjun Dong (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations. Rivaroxaban and apixaban are a selective, direct factor Xa inhibit...